Preclinical studies demonstrate that intratumoral delivery of adenovirus expressing IL-2 eradicates pre-established tumors in mice and confers immune protection from rechallenge. To explore the activity of AdCAIL-2 in prostate cancer, a Phase I clinical trial was conducted in patients with localized disease and Gleason score 47 or prostate-specific antigen (PSA) 410 plus Gleason score 7. A total of 12 patients were injected 4 weeks prior to prostatectomy in a dose-escalation study at doses of 10 9 , 5 Â 10 9 and 10 10 PFU of virus. No dose-limiting toxicity was observed. Side effects included perineal discomfort, hematuria, flu-like symptoms in two patients and urinary hesitancy in one patient. Pathology demonstrated an inflammatory response consisting predominantly of CD3+CD8+ T lymphocytes with areas of tumor necrosis. Intracellular cytokine staining of tumor-infiltrating lymphocytes demonstrated increases in both g-interferon and IL-4 secreting T cells after vaccination. PSA levels fell in five of five evaluable patients treated at the lowest dose (mean decline of 33.3%, range 17-69%). At higher doses, PSA values initially increased after injection, then fell to baseline prior to surgery. This trial demonstrates the feasibility and safety of intraprostatic adenovectormediated IL-2 gene delivery.
I n many developed countries, carcinoma of the prostate is the most commonly diagnosed malignancy in males and the second leading cause of cancer-related deaths. 1 Treatment strategies such as radical prostatectomy, local radiotherapy and brachytherapy are potentially curative for localized disease. 2, 3 However, up to 1/3 of patients initially diagnosed with clinically localized disease and treated with conventional therapy may develop metastases. 4 Numerous studies have attempted to identify factors that predict for an elevated risk of recurrence following surgery. Among the most consistently identified high-risk factors are preoperative prostate-specific antigen (PSA), histological grade as defined by Gleason score and DNA ploidy. [5] [6] [7] Thus far, available treatments for metastatic prostate cancer have failed to demonstrate significant curative potential, reinforcing the need for alternative treatment strategies for patients with high-risk localized disease. One novel strategy being evaluated is the use of immunotherapy to eradicate clinically localized tumor and distant micrometastatic disease.
Prostate cancer presents a unique opportunity for the development of immunological approaches to treatment. Prostate cancer cells express several tissue-specific proteins including PSA, prostate-specific membrane antigen (PMSA) and prostatic acid phosphatase (PAP) that can potentially function as target antigens for immunotherapy. However, it is also evident that prostate cancer is a slow growing tumor of low immunogenicity with no known cases of spontaneous regression. The low immunogenicity of prostate cancer may be due to a defect in cell-surface expression of class I major histocompatibility complex (MHC). 8 By providing exogenous cytokines not dependent on MHC-class I antigen processing (e.g. IL-2 and GM-CSF) it may be possible to overcome or prevent anergy of the immune effector cells. Systemic delivery of recombinant IL-2 induces clinical responses in various refractory malignancies. 9 However, its clinical use is limited by a short half-life and significant toxicity. To circumvent these problems, local delivery of low doses of IL-2 has been investigated in animal models including the Dunning rat model of prostate cancer. 10, 11 In situ administration of IL-2 mediated antitumor activity and decreased tumor growth without the side effects asso-ciated with systemic administration. As a more effective method of achieving high levels and prolonged intratumoral concentrations of IL-2, attention has turned to the use of gene delivery systems. Such a vaccine strategy using IL-2 gene-modified irradiated tumor cells injected intradermally in the Dunning rat model of prostate cancer led to prolonged survival in all rats and protected the animals from subsequent tumor challenge. 12 In previous work we have demonstrated successful in vivo adenoviral-mediated gene transfer of immunostimulatory molecules into primary human tumors. 13, 14 Furthermore, Phase I clinical trials of an adenovirus expressing IL-2 (AdCAIL-2) demonstrated safety of administration as well as bioactivity of the treatment. On the basis of these preclinical and clinical studies, we initiated a Phase I dose-escalation study of in situ AdCAIL-2 administration for patients with localized, high-risk prostate cancer. Adenovector was directly injected into the prostate 4 weeks prior to prostatectomy. This report describes toxicities and details both clinical and immune responses of patients treated with AdCAIL-2.
Patients and methods

Clinical protocol and study design
The primary end point of this trial was to establish the safety and toxicity of intraprostatic AdCAIL-2 administration in a Phase I dose-escalation study. Secondary objectives were to document local and systemic immune and clinical responses in patients treated with AdCAIL-2. The clinical protocol was approved by the University of Toronto Institutional review board and by the Health Protection Branch of Canada. Patients with poor prognosis, localized prostate cancer received a single intraprostatic injection of AdCAIL-24 weeks prior to preplanned radical prostatectomy. Escalating doses of recombinant adenovirus were administered in a traditional Phase I dose-escalation schema. All patients gave written, informed consent before initiation of treatment.
Patients
Patients with histologically documented, clinically localized prostate cancer scheduled to undergo radical prostatectomy were entered into the trial. Entry criteria required disease characteristics associated with an increased risk of postoperative recurrence based on a preoperative PSA of greater than 10 ng/ml and Gleason score of 7 or a Gleason score of greater than 7. The following clinical evaluations were performed prior to treatment, on days 1, 2, 14 and 28 or immediately prior to prostatectomy: history and physical examination, complete blood count (CBC) and differential, serum electrolytes, creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, albumin, total protein, PT/PTT, CD4 and CD8 counts, rheumatoid factor and antinuclear antibody.
Adenovirus and vaccine administration
AdCAIL-2 has been studied in a previous Phase I breast cancer and melanoma trial and the construction, production and activity of this vector have been described previously. 13, 14 Clinical-grade AdCAIL-2 viral supernatant is packaged at 1 Â 10 10 PFU/ml (PFU: plaque forming unit) and contains 1-10 PFU of detectable wildtype virus in 1 Â 10 9 PFU of viral vector. Each patient entered into the study received 2.5 ml injections of virus diluted in saline into each lobe of the prostate. Three patients were initially treated with the starting dose of 1 Â 10 9 PFU and observed for 28 days. In the absence of prohibitive toxicity, the next AdCAIL-2 dose was increased to 5 Â 10 9 PFU. Dose escalation continued to a maximum dose of 1 Â 10 10 PFU. Serum PSA values as a measure of disease and response were obtained on days 0, 1, 14, 28 and at 3-month intervals following surgery. Toxicity was graded according to the National Cancer Institute of Canada CTG expanded common toxicity criteria. To confirm results indicating a decline in PSA levels obtained at the lowest treatment dose, a further four patients were subsequently enrolled at the 1 Â 10 10 PFU dose (12 patients were therefore treated on study). As a result the statistical power to detect a significant decrease in the PSA level using a one sample ttest (alpha ¼ 0.05, two sided) increased from 0.55 to over 0.99 (NCSS PASS 2000).
Pathology and immunohistochemistry
All tumor biopsies obtained at baseline and surgical specimens obtained at the time of prostatectomy were evaluated for an inflammatory response by histology. Standard pathological assessment was carried out on slides stained with hematoxylin and eosin (H&E). Staining for specific T-cell subsets was performed using the following primary antibody reagents: rabbit polyclonal anti-human CD3, and monoclonal anti-CD4 (clone OPD4), -CD20 (clone L26) (all from Dako, Carpenteria, CA); anti-CD8 (clone 4B11) (Novocastra Laboratories, Newcastle-upon-Tyne, UK); anti-CD56 (Zymed Laboratories, San Francisco, CA).
Interleukin-2 expression
All biopsy and surgical specimens were assessed for the expression of IL-2 at the mRNA and protein level. IL-2 was detected in serum and in the supernatant of homogenized tumor biopsies and surgical specimens using a commercial Quantikine ELISA kit (R&D Systems, Minneapolis, MN). Samples were run as single observations only. Also, tumor cells were examined for hIL-2 mRNA by reverse-transcriptase PCR. RNA was extracted (Qiagen, Chatsworth, CA) from surgical specimens and oligo-dT reverse transcribed. The sequence of the sense and antisense primers used and details of PCR conditions have been described previously. 14 
PCR-based detection of AdCAIL-2
In addition, four representative prostatectomy specimens were analyzed for the presence of Ad vector DNA at 1 month following AdCAIL-2 injection. PCR-based detection of AdCAIL-2 was based on targeting a 487 bp sequence spanning the CMV promoter and the IL-2 portion of the IL-2 expression cassette and was performed using primers and conditions previously reported.
14 DNA was isolated from the clinical samples using the Easy DNA Isolation Kit Protocol 3 (Invitrogen, St Louis, MO). As a control, a mock DNA extraction was undertaken at the same time as clinical sample handling and was similarly subjected to PCR amplification. Using serial dilutions of clinical stock of AdIL-2, we have previously reported a detection level of 1.5 Â 10 4 PFU of AdIL-2 on ethidium gels and 1.5 Â 10 3 PFU by Southern analysis for this PCRbased assay.
Intracellular cytokine studies of vaccine site biopsies
Prostate specimens obtained prior to vaccination and at the time of radical prostatectomy were mechanically dissociated, and the resulting cell suspension was stored in liquid nitrogen. Prostate samples from both time points were evaluated concurrently for any one patient. Cytokine production from prostate-infiltrating lymphocytes was investigated by analyzing unstimulated cells or cells stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma, St Louis, MO) and 1 mg/ml of the calcium ionophore, A23187 (Sigma). Prior to incubation in 5% CO 2 at 37 o C for 5 hours, 0.7 ml/ml of the protein transport inhibitor GolgiStop TM (PharMingen, Mississauga, ON, Canada) was added to the cell suspension. Samples were then washed with staining buffer (Dulbecco's PBS, 1% FCS and 0.09% sodium azide, pH 7.5) and labeled with fluorochrome-conjugated antibodies specific for cell-surface antigens (0.25 mg FITC-, CyChrome TM or PEanti-CD3, CD4 or CD8, Becton Dickinson, San Jose, CA). Following a 30-minute incubation at 41C, the cells were washed and then fixed and permeabilized with 250 ml of Cytofix/Cytopermt (PharMingen, Mississauga, ON, Canada) for 20 minutes at 41C. The cells were subsequently washed twice, resuspended in 100 ml of Perm/ Washt solution, divided into two aliquots and labeled with either 0.25 mg of anti-IFN-g FITC and 0.25 mg IL-4 PE (Becton Dickinson, San Jose, CA) or isotype control. After a 30-minute incubation at 41C, the cells were washed in Perm/Wash TM solution and resuspended in staining buffer prior to analysis. Flow cytometry was performed on a FACScan (Becton Dickinson, Meylan, France) using Cell Quest software to acquire data and ModFit LT software analysis. Light scatter properties and CD3 staining were used to define the lymphocyte population.
Antiadenovirus antibody titers
Baseline serum samples and samples taken during followup visits were analyzed for antiadenovirus titers by ELISA as previously described. 13 
Dendritic cell (DC) generation
Blood was drawn from patients prior to vaccination and on days 7, 14, 21 and 80 thereafter. PBMCs were isolated by Ficoll-Hypaque density-gradient centrifugation at each time point. After a 1-hour, 371C incubation step in tissue culture flasks, adherent and nonadherent cells were separated and stored in liquid nitrogen until use. For the generation of DCs, adherent PBMC obtained from all time points were pooled and cultured in AIM-V (Gibco BRL, Burlington, ON, Canada) and supplemented with 10% autologous serum or human AB serum, 1% penicillin-streptomycin (Gibco BRL) and stimulated with 50 ng/ml hGM-CSF and 25 ng/ml hIL-4. On day 6 of culture, 10 ng/ml hTNF-a was added. All cytokines for DC culture were purchased from R&D systems (Minneapolis, MN). DCs were then pulsed overnight with autologous tumor lysate (50 mg protein/10 6 DC) prepared by freeze-thawing of tumor biopsy samples. Controls consisted of DCs pulsed with allogenic tumor lysate or unpulsed cells. On days 6 and 7 of culture, the phenotype of immature and mature DCs was analyzed by flow cytometry using anti-HLA-DR-PerCP, anti-CD1a-PE and anti-CD83-FITC (Becton Dickinson, San Jose, CA).
Lymphocyte proliferative response
In vitro autologous T-cell proliferative responses to tumor-pulsed DCs were studied. Nonadherent PBMCs collected prevaccination and on days 7, 14, 21 and 80 postvaccination were evaluated concurrently for any one patient. PMBCs were resuspended in serum-free AIM-V media and cultured with tumor-pulsed DCs (generated as described above) at a ratio of 10:1 and plated at a cell density of 1 Â 10 5 /well in 96 microtiter plates (Fischer, Mississauga, ON, Canada). DCs were irradiated with 25 Gy (Gammacell 3000 ELAN, NORDION International Inc., Kanata, ON, Canada) before coculturing with nonadherent PBMC. Positive controls included PMBCs cocultured with allogenic tumor-pulsed DCs, while negative controls consisted of PMBCs cocultured with unpulsed DCs, PMBCs alone or DCs alone. All groups were plated in triplicate. The cells were incubated for 6 days at 37 o C with 5% CO 2 and then pulsed with 0.5 mCi of 3 H-thymidine (Amersham Pharmacia Biotech, Piscataway, NJ). After 16 hours, the cells were harvested onto glass fiber filters using a PHD TM Cell Harvester (Cambridge Technology Inc, Cambridge, MA) counted in an LS1801 scintillation counter (BECKMAN, Mississauga, ON, Canada). The mean counts per minute (cpm) were calculated for triplicate measurements. Data were analyzed after conversion to proliferation indices (PI). PI ¼ (cpm of responder PBMCs+DCs)À(cpm of DCs alone)/(cpm of PBMCs in culture alone).
Cytokine production response
INF-g release and intracellular cytokine response of peripheral blood lymphocytes to pulsed DCs were assessed. The procedure was identical to that described above, with the exception that on day 7 of coculture of PBMCs with DCs, 150 ml supernatant was removed for evaluation of IFN-g secretion using the OptEIA TM Human IFN-g ELISA kit (PharMingen, Mississauga, ON, Canada). For analysis of intracellular cytokine release, the cocultured cells were treated for 5 h with 7 ml/mg of GolgiStop TM and then harvested for intracellular INF-g assay as described above.
Results
Patient characteristics
A total of 12 patients with prostate cancer treated at our institution were enrolled in this Phase I immuno-gene therapy study for patients with high-risk localized disease. Details of patient demographics, disease characteristics and dose level are summarized in Table 1 . As defined by PSA and/or histological grade at diagnosis, all patients exhibited features predicting for an elevated risk of recurrence. AdCAIL-2 doses were escalated as described in the Patients and methods section so that each patient received 1 Â 10 9 , 5 Â 10 9 or 1 Â 10 10 PFU of AdCAIL-2 per injection. A dispensing error occurred at the 5 Â 10 9 dosing level wherein patient 6 received 1 Â 10 10 PFU in error. Since the patient exhibited no toxicity, a decision was made to continue dose escalation to the next planned level. Thus two patients are presented at dose level 5 Â 10 9 and three patients at dose level 10 10 PFU.
Toxicity
The immunotherapy produced only minor adverse reactions, with the majority of patients experiencing no side effects or complications. Only one patient exhibited grade 3 toxicity. This patient was inoculated with 1 Â 10 9 PFU of adenovector and developed a lymphopenia of 0.5 (10 9 / l) 2 days postinjection. The abnormalities in the CBC were detected as a matter of routine follow-up testing. All abnormal lab values described in the trial (Table 2) were Although liver toxicity has been described in animal and human studies of adenovirus gene delivery, we did not observe any abnormalities in liver function including PT/PTT. Minor systemic complaints consisting of flu-like symptoms were observed in two patients (at dose levels 5 Â 10 9 and 1 Â 10 10 PFU). These side effects resolved within 48 hours and did not require intervention. Overall, the injections were well tolerated; however, the majority of patients complained of discomfort at the time of inoculation and two patients experienced gross hematuria, symptoms likely related to the injection itself. One patient treated at the highest dose level experienced urinary hesitancy that persisted for 5 days. Review of surgical field in this patient showed significant inflammation and likely accounted for the patient's symptoms after vaccination. In no instances were adverse reactions prohibitive to dose escalation or discontinuation of the study. Safety testing for replication-competent adenovirus or shed adenovector in the blood, saliva or stool of patients was performed as in our previous studies and was negative for the entire study population.
13,14
Local immune responses
Surgical specimens from all 12 patients taken at the time of prostatectomy (4 weeks after inoculation with Ad-CAIL-2) were characterized histologically by an infiltrate of CD3-positive T cells (Fig 1) . Differential staining with CD4 and CD8 antibodies showed a preponderance of CD8-positive cells. Although it is possible that this observation is the consequence of an immune response mediated by IL-2 transgene expression, the lack of control group for Ad vector limits the conclusions of this finding.
IL-2 protein was not detectable in the supernatant of homogenized tissue taken 1 month after intraprostatic injection. Similarly, we were unable to demonstrate expression of vector-derived IL-2 by RT-PCR of RNA extracted from prostatectomy samples. These findings are entirely consistent with the known pattern of adenovector-derived transgene expression, with maximum expression occurring 2-3 days after infection and decreasing to undetectable levels after 14 days. It is clear, therefore, that to demonstrate transgene expression, the trial design would have required performing biopsies on patients just days after painful intraprostatic injection, exposing the patients to added risks of infection and discomfort. To substantiate our results therefore, we refer to similar clinical trials in which we clearly demonstrate transgene expression of IL-2 protein after in vivo vaccination with this same adenovirus. 13, 14 Furthermore, efficient adenoviralmediated gene delivery into prostate cell lines is well documented. 15 Although vector-derived IL-2 RNA or protein was not present 1 month after AdCAIL-2 injection, PCR using oligonucleotide primers from the CMV promoter and from the hIL-2 minicassette detected Ad 1 month after adenovector injection in one of the four representative surgical specimens selected for testing. Thus, Ad vector DNA can persist for at least 1 month in some patients postinjection. Failure to detect AdCAIL-2 vector from the majority of the patients, 1 month after vaccination, likely reflects the clearance of infected cells.
To further assess the local immune response to AdCAIL-2 vaccination, we analyzed cytokine secretion by T cells in four patients in whom adequate pre-and postsurgical material was obtained. Tumor-infiltrating lymphocytes were stimulated with PMA and A23187, and intracellular IFN-g and IL-4 production was measured by flow cytometry. Concurrently, tumor-infiltrating lymphocytes were phenotyped and enumerated after differential labeling with CD4 and CD8 antibodies. As shown in Table 3 and in agreement with immunohistochemical studies, we saw a consistent increase (range 2.6 to 13.7-fold increase) and preponderance of CD8-positive T cells over CD3/CD4 cells after vaccination. Similarly, we demonstrated marked increases in INF-g secreting cells and a more moderate increase in IL-4-secreting tumorinfiltrating lymphocytes in postvaccine prostate specimens. 
Systemic immune responses
Assessment of the patient's general immune status disclosed changes in number but not proportion of circulating CD3/CD8T lymphocytes as assessed by flow cytometric analysis. CD3/CD8 counts fell from baseline levels in the 24 hours following injection of AdCAIL-2 (from a median of 338.337175.42 to 241.227126.32), a decline that did not reach statistical significance (P ¼ .07), before returning to baseline by day 14 postvaccine administration. Still this observation is entirely consistent with an acute phase reaction. Similarly a transient but less obvious decrease in the number of CD3/CD4-positive cells (from a median of 718.787377.30 to 577.117 286.59) was also observed but was also nonsignificant (P ¼ .13). No consistent changes in post-treatment circulating monocyte or eosinophil counts were noted among the study population. We detected a clinically trivial, but statistically significant, increase in serum IL-2 levels measured 2 days postinjection as compared to pretreatment values (from 13.76+6.67 to 19.00+11.61 pg/ml; P ¼ .008).
To exclude the generation of autoantibody formation, patients were tested for the presence of antinuclear antibodies (ANA) and rheumatoid factor (Rf) before and after injections. ANA assays at both time points were negative in all patients. One patient testing negative for Rf before injection became weakly positive after vaccination and when later retested was negative.
As a measure of host humoral response to adenovector injection, patient serum was monitored serially for antiadenovirus (anti-Ad) IgG production. All patients tested had detectable anti-Ad IgG antibodies prior to vaccination, albeit at relatively low levels (Fig 2) . After injection, a consistent rise in anti-Ad IgG antibody titer was observed in the study population. There was a trend toward a greater anti-Ad response in patients with higher baseline levels of anti-Ad IgG and patients who received higher dose levels of AdCAIL-2.
Planned tumor-specific immune response studies were limited by the small number of cells recovered from pretreatment prostate biopsies. Nevertheless, we were able to complete longitudinal analysis of tumor-specific responses in three patients (numbers 4, 6 and 7). All three patients demonstrated a similar pattern of increased T-cell proliferation and IFN-g production in response to tumor lysate pulsed DCs (Fig 3) . Importantly, however, unpulsed DCs induced a similar response demonstrating that such up-regulation of immune reactivity is relatively generalized and cannot be classified as tumor specific in nature.
Tumor Response
Patient sera for PSA determination were obtained on the day of study entry and on days 1, 14 and 28 or just prior to radical prostatectomy. Of the 12 patients vaccinated, 10 were evaluable. The initial PSA level of patient 9 was very low and therefore not a viable criteria for monitoring response, while patient 10 had insufficient serum collections for longitudinal analysis. Figures 4 and 5 plot serum PSA levels for each evaluable patient. At the lowest dose level (1 Â 10 9 PFU) five of five evaluable patients demon- Gene therapy for prostate cancer S Trudel et al strated a decline in PSA (mean 33%, range 17-69%; P ¼ .03). One patient injected with a dose of 1 Â 10 9 PFU (patient 2) demonstrated a precipitous fall in serum PSA with treatment (from 18.6 to 5.1 ng/ml 1 month postvaccine administration). At the onset of this study, only three patients were scheduled to receive a vaccine dose of 1 Â 10 9 PFU. However, after all three patients demonstrated a decline in PSA, a further four patients were enrolled at this dose level to confirm this observation (see the section Patients methods). At higher AdCAIL-2 doses (5 Â 10 9 and 1 Â 10 10 PFU), PSA levels increased significantly in three of the five evaluable patients, 1-14 days after injection and returned to baseline levels prior to prostatectomy. Given the downward trend in serum PSA in these patients, a further decline in PSA, beyond baseline levels, may have been detected in these patients if it had been possible to sample additional time points by extending the time to prostatectomy. Serum PSA values fell to undetectable levels in 11 of the 12 patients after cytoablative surgery.
Clinical outcome
The median follow-up for this trial is 18 months (range 3-16 months) from study entry. Several patients have received adjuvant therapy after prostatectomy. Hormonal manipulation (androgen ablation) and adjuvant radiotherapy were initiated following prostatectomy in patients 9 and 10 because of positive resection margins. Similarly, patient 7 continues to receive hormonal therapy as a result of a persistently detectable PSA after prostatectomy. To date, all patients continue to have trace to undetectable PSA levels and there has not been any indication of disease relapse. Gene therapy for prostate cancer S Trudel et al
Discussion
Metastatic prostate cancer is a major cause of death and remains incurable using conventional therapies raising the need for alternative treatment strategies. One such strategy being evaluated by a number of groups is the use of immunotherapy. [16] [17] [18] In this trial, we examined the use of in situ immuno-gene therapy for patients with locally advanced prostate cancer as adjuvant therapy to radical prostatectomy.
Our results indicate that in situ cytokine gene transfer using an adenoviral gene delivery system had minimal toxicity in this small Phase I study. One transient occurance of grade 3 lymphopenia without adverse clinical outcome was observed. Thus, this approach provides a practical and safe alternative to related gene therapy strategies using autologous tumor cells. A significant limitation of the latter approach is the difficulty encountered in establishing primary cell cultures to serve as the target for ex vivo gene transfer. 19 The requirements for surgery to obtain adequate tumor volumes for vaccine production, the unreliable tumor cell yield and the expense of creating tumor cell cultures for each treated subject limit the widespread applicability of this therapy. On the other hand, an in vivo transduction approach is limited by the rapid development of cellular and humoral responses to adenoviral gene products and the resulting rapid clearance of vector and diminished transgene expression.
It is of note then that despite the pre-existing immunity to adenovirus and the rapid development of anti-Ad antibodies observed in this trial, a generalized immune response in tumor biopsies was still evident 1 month after administration of vector as was the presence of Ad vector. Indeed, preclinical studies in immunocompetent mouse models demonstrate that pre-existing immunity to adenovirus did not significantly limit the initial therapeutic effects of such therapy. 20 Nevertheless, if future trials are to use sequential dosing schedules, vector readministration is likely to be associated with diminished duration of transgene expression and possibly increased toxicity raising the need for less immunogenic adenoviral vectors. 21 Patient immune parameters studied in this trial suggest that the vector dosages employed were immunogenic (at least to adenovector coat proteins) in vivo. We demonstrated recruitment of cytotoxic (CD3-, CD8-positive) T cells into the tumor bed and a corresponding increase in intracellular cytokine production after vaccination. We believe that cytotoxic-mediated cell lysis and tumor necrosis accounted for the changes in PSA values observed in the majority of patients. However, the degree to which the inflammatory response was antiadenovector or antitumor cannot be further assessed, although the former seems more likely. The lack of an ideal control group limits the conclusions that can be drawn from this finding.
Immunological monitoring of systemic responses to AdCAIL-2 further suggests a capacity of the injection to stimulate generalized immunity. Such an effect likely results from proinflammatory and Th1 cytokines secreted as a consequence of both innate and adaptive responses to adenovirus. Tumor-specific immune reactivity was not documented in the three patients whose serial immune response could be followed in this trial. It must be noted however that these studies were undertaken in non-PSA responders and therefore it is impossible to draw firm conclusions from this Phase I data.
Although further studies are necessary to examine whether AdCAIL-2 can lead to the development and/or amplification of functional tumor-specific immune responses, this trial does demonstrate some clinically relevant consequences of vector injection. At 4 weeks of follow-up after injection, five of 10 evaluable patients (five of five at 10 9 PFU of vector) demonstrated an unambiguous decline in serum PSA. Belldegrun et al 22 have similarly reported transient PSA responses to intraprostatic inoculation with plasmid DNA coding for IL-2, suggesting that the responses observed in this study are generalizable and supporting the contribution of adenovector-derived IL-2 as the primary effector. Although routinely used as a surrogate end point for clinical efficacy, there is no standardized definition of PSA response. 23 Nevertheless, a decline in PSA of more than 50% is generally accepted as a marker of antitumor activity. 24 While only one patient exhibited such a response, it is possible that a further decline in PSA would have been observed in some patients with additional follow-up. Furthermore, trials in neuroblastoSerum PSA (ng/mL) Days Post Injection Figure 5 PSA levels after vaccination. Serum PSA levels measured in patients who received either 5 Â 10 9 or 1 Â 10 10 PFU of AdCAIL-2 were determined preinjection and on days 1, 14 and 28 postvaccine.
Gene therapy for prostate cancer S Trudel et al ma patients employing IL-2 expressing tumor cell vaccines have shown progression from stable to complete responses more than 6 weeks after vaccination suggesting that longer follow-up is necessary in trials of this type. 25 Our preliminary clinical results of in situ AdIL-2 gene therapy demonstrate PSA decreases ranging from 17 to 69% from initial values. The biologic mechanisms underlying such PSA declines are unknown and cannot be attributed to a cytokine-induced antitumor response at this time. Current studies at our center are focused on understanding these responses and increasing the benefits of such an approach. In animal models, synergistic and enhanced antitumor responses to the combination of IL-12 and the costimulatory molecule CD80, as compared to either agent used alone, have been reported. 26 We are hopeful that these molecular combinations will prove effective in future clinical trials.
